© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
John F. R. Robertson, MD, discusses overall survival data from the phase II FIRST study, which looked at fulvestrant as first-line therapy for patients with advanced breast cancer.
John F. R. Robertson, MD, professor of surgery, faculty of medicine & health sciences, The University of Nottingham, United Kingdom, discusses overall survival data from the phase II FIRST study, which looked at fulvestrant as first-line therapy for patients with advanced breast cancer.
<<<